Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
TMDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$55.00 - $177.37
Previous CloseN/A
Volume1.17M
Average Volume (3M)1.01M
Market Cap
$4.83B
Enterprise Value$1.69B
Total Cash (Recent Filing)$310.14M
Total Debt (Recent Filing)$518.41M
Price to Earnings (P/E)105.0
Beta1.43
Next Earnings
Jul 31, 2025EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding33,833,790
10 Day Avg. Volume784,193
30 Day Avg. Volume1,010,960
Financial Highlights & Ratios
PEG Ratio2.18
Price to Book (P/B)9.74
Price to Sales (P/S)0.00
P/FCF Ratio-31.60
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue1.00
Enterprise Value/Gross Profit5.82
Enterprise Value/Ebitda7.43
Forecast
1Y Price Target
$124.00Price Target Upside-13.21% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering8
TransMedics Group News
PremiumCompany Announcements
TransMedics Group Holds 2025 Annual Shareholders Meeting
PremiumCompany Announcements
TransMedics Group Reports Robust Q1 2025 Growth
Bulls Say, Bears Say
Bulls Say
Financial PerformanceUS sales are estimated to be $173M, up by approximately 60% year over year.
Market ExpansionFDA approval to expand OCS Liver's label is expected, which could significantly increase on-label usage.
Transplant Market GrowthTransplant data from UNOS showed strong growth in heart and DCD liver trends, which is a positive indicator for TMDX.
Bears Say
Heart Transplant TrendsThere is a decline in heart transplants.
Regulatory ChallengesThe interim response to the citizen petition, expected to be neutral, is considered a de facto negative.
Transplant Segment PerformanceTotal lung transplants declined by 1% month-over-month, and DCD lung transplants declined 17% month-over-month, indicating a weaker performance in this segment for TMDX.
Ownership Overview
3.58% Insiders
36.03% Mutual Funds
24.32% Other Institutional Investors
11.63% Public Companies and Individual Investors
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $55.00 and its highest was $177.37 in the past 12 months.
What is TransMedics Group Inc’s market cap?
TransMedics Group Inc’s market cap is $4.83B.
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is Jul 31, 2025 which is in 45 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on May 08, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.264 by $0.436.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Overvalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is 0.45.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 33,833,790 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $0.7 in its last earnings report, beating expectations of $0.264. Following the earnings report the stock price went up 19.635%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Currently, no hedge funds are holding shares in TMDX
TransMedics Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$124.00 (-13.21% Downside)
$124.00 (-13.21% Downside)
Blogger Sentiment
Bullish
TMDX Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.36%
12-Months-Change
Fundamentals
Return on Equity
22.99%
Trailing 12-Months
Asset Growth
15.71%
Trailing 12-Months
Company Description
TransMedics Group Inc
TransMedics Group, Inc. is a medical technology company that specializes in developing advanced organ transplant systems. The company is renowned for its Organ Care System (OCS), which is designed to improve outcomes for organ transplant patients by enabling enhanced preservation, assessment, and transportation of donor organs. Operating primarily within the healthcare and medical technology sectors, TransMedics aims to address the limitations of traditional cold storage methods and expand the availability of viable organs for transplantation.
TMDX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and operational efficiency improvements, particularly in the U.S. market and logistics services. However, challenges remain in international revenue growth, service gross margin, and managing increased operating expenses. Despite these lowlights, the overall outlook is positive with raised revenue guidance and significant strategic advancements.Read More>TMDX Stock 12 Month Forecast
Average Price Target
$124.00
▼(-13.21%Downside)